Keywords
Chronic renal failure
Pharmacovigilance
Long-term adverse effects
Interstitial nephritis
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To investigate the scientific literature related to the association between prolonged use of proton pump inhibitors (PPIs) and the risk of kidney disease. Methods: This is an integrative literature review of articles published between 2019 and 2024, in Portuguese or English and with free full text. The guiding question was used: What is the relationship between the prolonged use of PPIs and the increased risk of kidney disease? The research was carried out in December 2024, in the databases of the Virtual Health Library (VHL), SciELO, PUBMED and LILACS, through the Health Sciences Descriptors (DeCS): Proton Pump Inhibitors, Chronic Renal Failure, Pharmacovigilance, Long-Term Adverse Effects and Interstitial Nephritis associated with the Boolean operator “AND”. Results: 23 articles met the inclusion and exclusion criteria, in which the risk of developing kidney diseases is associated with the prolonged use of PPIs. Final considerations: PPIs are effective in treating gastrointestinal conditions, but prolonged use is associated with adverse events. Judicious use and continuous monitoring are essential to reduce risks. However, the scarcity of longitudinal studies and the variability in renal monitoring methods make it difficult to generalize the results.
References
BEN-ELTRIKI M, et al. Do proton pump inhibitors increase mortality? A systematic review and in-depth analysis of the evidence. Pharmacology Research and Perspectives, 2020; 8(5).
BHATNAGAR MS, et al. Long-term use of proton-pump inhibitors: Unravelling the safety puzzle. Cureus, 2024; 16(1): e23334.
BONGERS F, et al. A importância da formação de enfermeiros e da qualidade dos serviços de saúde. Revista Eletrônica Acervo Enfermagem, 2018; 1: 1-8.
CASTELLANA C, et al. Side effects of long-term use of proton pump inhibitors: Practical considerations. Polish Archives of Internal Medicine, 2021; 131(6): 541–549.
CHOLIN L. Do proton-pump inhibitors cause CKD and progression of CKD?: CON. Kidney360, 2022; 3(7): 1137–1140
CHINZON D, et al. Safety of long-term proton pump inhibitors: facts and myths. Arquivos de Gastroenterologia, 2022; 59(2): 219–225.
OLIVEIRA GK, et al. O uso do omeprazol: uma avaliação dos efeitos da administração prolongada do medicamento. Revista Eletrônica Acervo Saúde, 2018.
EDINOFF AN, et al. Proton pump inhibitors, kidney damage, and mortality: an updated narrative review. Advances in Therapy, 2023; 40(6): 2693–2709.
EUSEBI LH, et al. Proton pump inhibitors: risks of long-term use. Journal of Gastroenterology and Hepatology, 2017; 32(7): 1295–1302.
FOSSMARK R, et al. Adverse effects of proton pump inhibitors—evidence and plausibility. International Journal of Molecular Sciences, 2019; 20(20).
HAASSTRUP PF, et al. When does proton pump inhibitor treatment become long term? A scoping review. BMJ Open Gastroenterology, 2021; 8(1).
IMPARATO RR, et. al. Proton pump inhibitor deprescription: a rapid review. Brazilian Journal of Pharmaceutical Sciences, 2022; 58.
JAYNES M, KUMAR AB. The risks of long-term use of proton pump inhibitors: a critical review. Therapeutic Advances in Drug Safety, 2019; 10.
LAM JR, et al. Uso de inibidor da bomba de prótons e antagonista do receptor de histamina 2 e deficiência de vitamina B12. JAMA, 2013; 310(22): 2435-2442.
LIMA JMD, et al. Uso do omeprazol: estudo descritivo de pacientes idosos de uma Unidade de Saúde da Família (USF) de Ribeirão Preto, SP, Brasil. Infarma-Ciências Farmacêuticas, 2019; 31(1): 46-53.
KIM SG, et al. Non-indicated initiation of proton pump inhibitor and risk of adverse outcomes in patients with underlying chronic kidney disease: a nationwide, retrospective, cohort study. BMJ Open, 2024; 14(1).
LIAEBEUF S, et al. Resultados adversos dos inibidores da bomba de prótons em pacientes com doença renal crônica: o estudo de coorte CKD-REIN. British Journal of Clinical Pharmacology, 2021; 87(7): 2967–2976.
LAZARUS B, et al. Proton pump inhibitor use and the risk of chronic kidney disease. JAMA Internal Medicine, 2016; 176(2): 238–246.
MAIDEEN NMP. Adverse Effects Associated with Long-Term Use of Proton Pump Inhibitors. Chonnam Medical Journal, 2023; 59(2), 115.
MERTZ A, et al. Discontinuation of proton pump inhibitors in patients with chronic kidney disease. Hospital Pharmacy, 2021; 56(4): 308–313.
MORSCHEL CF, et al. The relationship between proton pump inhibitors and renal disease. Brazilian Journal of Nephrology, 2018; 40(3): 301–306.
NUGENT CC, et al. H2 blockers. StatPearls Publishing, 2023; 17 ago. Disponível em: www.ncbi.nlm.nih.gov/books/NBK525994. Acesso em: 5 fev. 2025.
PARMAR MP, et al. Impacto dos inibidores da bomba de prótons na função renal e na progressão da doença renal crônica: uma revisão sistemática. Cureus, 2023; 15(12): e49883.
PERAZELLA MA. Proton pump inhibitors and kidney disease: what gives? Kidney360, 2024; 3(7): 1137–1140.
RAJAN P, et al. Risk of bias in non-randomized observational studies assessing the relationship between proton-pump inhibitors and adverse kidney outcomes: a systematic review. Therapeutic Advances in Gastroenterology, 2022; 15.
SANTOS AS, et al. Kidney function decline associated with proton pump inhibitors: results from the ELSA-Brasil cohort. BMC Nephrology, 2023; 24(1).
SILVA MR, et al. Monteverdia ilicifolia: um protetor gástrico. Arquivos de Ciências da Saúde da UNIPAR, 2022; 26(3): 1248–1266.
SOUZA MNA, et al. Trilhando o caminho do conhecimento: o método de revisão integrativa para análise e síntese da literatura científica, 2023.Observatório de La Economía Latinoamericana, 2023; 21(10): 18448–18483
SHANIKA LGT, et al. Proton pump inhibitor use: systematic review of global trends and practices. European Journal of Clinical Pharmacology, 2023; 79(9): 1159–1172.
VEETTIL SK, et al. Association of proton-pump inhibitor use with adverse health outcomes: A systematic umbrella review of meta-analyses of cohort studies and randomised controlled trials. British Journal of Clinical Pharmacology, 2022; 88(4): 1551–1566.
VENGRUS CS, et al. Proton pump inhibitors use and risk of chronic kidney disease and end-stage renal disease. Minerva Urology and Nephrology, 2021; 73(4): 462–470
WEIR MR, et al. Inibidores da bomba de prótons e doença renal: fato ou ficção? American Journal of Nephrology, 2024; 55(4): 499–507.
WU B, et al. Proton pump inhibitors associated acute kidney injury and chronic kidney disease: data mining of US FDA adverse event reporting system. Scientific Reports, 2021; 11(1): 16979.
XIA B, et al. Individualized prevention of proton pump inhibitor related adverse events by risk stratification. Nature Communications, 2024; 15(1).
YIBIRIN M, et al. Adverse effects associated with proton pump inhibitor use. Cureus, 2021; 13(12): e12759.
YEPURI G, et al.Proton pump inhibitors accelerate endothelial senescence. Circulation Research, 2016; 118(12): e36-e42.
ZATERKA, S.; EISIG, JN Tratado de Gastroenterologia: da Graduação à Pós-Graduação. 2ª ed. São Paulo: Ateneu, 2016; 1.550p.